Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896712 · ClinicalTrials.gov registry record · Phase 2
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
A Phase 2 study of Cocaine-Related Disorders, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT02896712: Completed Phase 2 study of Cocaine-Related Disorders, sponsored by The University of Texas Health Science Center, Houston.
NCT02896712 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 118 participants, above the 57-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (107% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02896712, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates. Second, for patients who do not respond to initial treatment, the investigators will examine whether dopamine-targeted pharmacotherapy is an effective augmentation strategy. Third, for patients who respond to initial treatment, the investigators will assess the relative benefit of continued treatment with Acceptance and Commitment Therapy in combination with Contingency Management, as compared to Drug Counseling in combination with Contingency Management, to prevent relapse.
Primary Outcome
Urine is assessed for levels of the cocaine metabolite benzoylecgonine (BE), and the drug screen is considered positive for cocaine use if BE level is ≥ 150 ng/mL.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Acceptance and Commitment Therapy (ACT)
- DRUG Modafinil
- BEHAVIORAL Contingency Management (CM)
- BEHAVIORAL Drug Counseling (DC)
Study Locations (1)
Texas
- UTHealth Center for Neurobehavioral Research on Addiction - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2021-09-13 |
| Phase | Phase 2 |
What the finished NCT02896712 record still lists
NCT02896712 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 57-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (107% higher).
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02896712 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02896712 about?
NCT02896712 is a clinical study titled "Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention". First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates. Second, for patients who do not respond to initial treatment, the investigators will examine whether dopamine-targeted pharmacothe...
What is the current status of trial NCT02896712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2016-11-18. Estimated completion is 2021-09-13.
What conditions does trial NCT02896712 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
What interventions are being tested in trial NCT02896712?
The interventions under investigation include: Placebo (DRUG), Acceptance and Commitment Therapy (ACT) (BEHAVIORAL), Modafinil (DRUG), Contingency Management (CM) (BEHAVIORAL), Drug Counseling (DC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02896712?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02896712 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02896712's enrollment target sits among peer trials
118 4th of 15 higher than 12 of 15 other Cocaine-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Evaluation of Benztropine for Cocaine Craving - 2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI